Needle-free Diabetes Care Market

By Device Type;

Treatment Devices - [Insulin Jet Injector, Insulin Pen, and Insulin Inhaler & Insulin Patch & Pump] and Diagnostic Devices - [Continuous Glucose Monitoring and Instant Glucose Monitoring]

By Treatment;

Oral Insulin, Inhaled Insulin, Insulin Patch, and Others

By Application;

Insulin Delivery and Other

By End User;

Diagnostic Centers, Hospitals & Clinics, and Others

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn127496696 Published Date: June, 2025 Updated Date: August, 2025

Needle-Free Diabetes Care Market Overview

Needle-Free Diabetes Care Market (USD Million)

Needle-Free Diabetes Care Market was valued at USD 17,781.21 million in the year 2024. The size of this market is expected to increase to USD 28,552.74 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.0%.


Needle-free Diabetes Care Market

*Market size in USD million

CAGR 7.0 %


Study Period2025 - 2031
Base Year2024
CAGR (%)7.0 %
Market Size (2024)USD 17,781.21 Million
Market Size (2031)USD 28,552.74 Million
Market ConcentrationMedium
Report Pages374
17,781.21
2024
28,552.74
2031

Major Players

  • Antares Pharma, Inc
  • Bioject Medical Technologies Inc
  • Injex Pharma Ag
  • Medical International Technology, Inc
  • National Medical Products Inc
  • Penjet Corporation
  • Zogenix

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Needle-free Diabetes Care Market

Fragmented - Highly competitive market without dominant players


The Needle‑Free Diabetes Care Market is seeing robust expansion, with adoption rising by over 43%, driven by growing patient preference for painless alternatives. Healthcare providers and clinics are integrating jet injectors, insulin patches, and inhaled insulin devices to improve compliance. Manufacturers are implementing focused strategies to penetrate both clinical and home-care segments. Strong collaboration with endocrinology networks supports scalable expansion.

Strategic Alliances Driving Validation and Access
Over 40% of new product development is supported by strategic collaborations between device firms, diabetes clinics, and research labs. These alliances streamline regulatory validation and improve product trust. Joint ventures and mergers are expanding market access and integrating solutions into diabetes care ecosystems. This synergy reinforces long‑term growth.

Expanding Adoption Across Care Settings
Usage of needle‑free diabetes devices has increased by more than 44% in hospitals, outpatient diabetes centers, and at‑home self‑care settings. Patients value precision, safety, and ease of use. Companies are spearheading growth strategies including bundled product offerings, provider education programs, and patient onboarding kits. Partnerships with health systems help scale delivery infrastructure and drive sustained expansion.

Smart and Connected Platforms Shaping Future Growth
More than 46% of device pipelines now feature integrated dose monitoring, remote connectivity, and AI‑based feedback systems—defining the market’s future outlook. These smart platforms support remote care, data‑driven glycemic management, and telehealth integration. Expansion strategies increasingly align with digital care models and precision medicine approaches.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Device Type
    2. Market Snapshot, By Treatment
    3. Market Snapshot, By Application
    4. Market Snapshot, By End User
    5. Market Snapshot, By Region
  4. Needle-Free Diabetes Care Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Rising Number of Diabetic Patients
        2. Discomfort with Traditional Methods
      2. Restraints
        1. High Costs
        2. Technical Concerns
      3. Opportunities
        1. Cost-Effective Devices
        2. Regulatory Approvals
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry

  5. Market Segmentation
    1. Needle-Free Diabetes Care Market, By Device Type, 2021 - 2031 (USD Million)
      1. Treatment Devices
        1. Insulin Jet Injector
        2. Insulin Pen
        3. Insulin Inhaler and Insulin Patch & Pump
      2. Diagnostic Devices
        1. Continuous Glucose Monitoring
        2. Instant Glucose Monitoring
    2. Needle-Free Diabetes Care Market, By Treatment, 2021 - 2031 (USD Million)
      1. Oral Insulin
      2. Inhaled Insulin
      3. Insulin Patch
      4. Others
    3. Needle-Free Diabetes Care Market, By Application, 2021 - 2031 (USD Million)
      1. Insulin Delivery
      2. Other
    4. Needle-Free Diabetes Care Market, By End User, 2021 - 2031 (USD Million)
      1. Diagnostic Centers
      2. Hospitals & Clinics
      3. Others
    5. Needle-Free Diabetes Care Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Antares Pharma, Inc
      2. Bioject Medical Technologies Inc
      3. Injex Pharma Ag
      4. Medical International Technology, Inc
      5. National Medical Products Inc
      6. Penjet Corporation
      7. Zogenix, Inc
      8. Others
  7. Analyst Views
  8. Future Outlook of the Market